List view / Grid view
6 January 2015 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use...
5 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration...
19 December 2014 | By Merck
Acquisition expands Merck’s oncology portfolio with novel oral BET inhibitor, OTX015...
19 December 2014 | By Roche
Roche announced top-line results of the Phase III MARIANNE study...
19 December 2014 | By Pfizer
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).
17 December 2014 | By Eli Lilly and Company
Eli Lilly and Company has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA(R) (ramucirumab)...
17 December 2014 | By GlobalData
The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData...
17 December 2014 | By Selvita
Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has successfully completed its Initial Public Offering...
16 December 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embolic Stroke of Undetermined Source, also called ESUS...
16 December 2014 | By The Cambridge Crystallographic Data Centre
Essential resource to scientists around the world reaches historic record...
16 December 2014 | By Abbott
Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Notes Offer"), in which it is offering to purchase for cash any and all of the outstanding $300 million aggregate principal amount of 5.125% Senior Notes due…
16 December 2014 | By kdm communications
The inaugural MicroTAS Video Competition, run by microfluidics specialist Dolomite and Lab on a Chip, and supported by the Chemical and Biological Microsystems Society, saw first prize awarded to an enterprising – and highly creative – entry submitted by Tijmen Hageman from the Korean Institute of Science and Technology (KIST)…
15 December 2014 | By Orange
The U.S. Agency for International Development and global telecommunications operator Orange announced a new alliance to develop innovations in mobile health (mHealth) at the Global mHealth Forum in Washington, DC...
15 December 2014 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
15 December 2014 | By Abbott
Abbott announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer...
